S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 08:11 PM ET

NVO

Novo Nordisk A/S

Price Chart
Latest Quote

$50.32

-1.16 (-2.25%)
Current Price
Previous Close $51.48
Open $51.06
Day High $51.40
Day Low $50.26
Volume 8,818,306
Fetched: 2026-07-18T00:11:45
Stock Information
Note: Financial values converted from DKK to USD
Quarterly Dividend / Yield $1.80 / 3.56%
Shares Outstanding 3.35B
Quarterly Dividend Yield 3.56%
Quarterly Dividend $1.80
Total Debt $22.40B
Cash Equivalents $3.31B
Revenue $50.16B
Net Income $18.66B
Sector Healthcare
Industry Drug Manufacturers - General
Market Cap $227.74B
P/E Ratio 12.35
EPS (TTM) $4.17
Exchange NYQ
🌐 Visit Website
Recent Price History
Date Close Volume
2026-07-17 $50.32 8,818,306
2026-07-16 $51.48 9,792,400
2026-07-15 $50.56 10,314,900
2026-07-14 $49.07 6,623,700
2026-07-13 $49.28 7,420,400
2026-07-10 $49.48 6,317,800
2026-07-09 $48.88 5,458,500
2026-07-08 $48.89 9,137,800
2026-07-07 $49.64 12,222,700
2026-07-06 $49.26 12,333,300
2026-07-02 $50.43 12,069,100
2026-07-01 $48.77 11,248,400
2026-06-30 $47.94 8,579,300
2026-06-29 $48.34 9,324,100
2026-06-26 $48.07 20,136,400
2026-06-25 $47.64 12,471,200
2026-06-24 $47.41 15,078,200
2026-06-23 $47.42 17,674,300
2026-06-22 $45.88 17,141,300
2026-06-18 $43.19 8,996,700
About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $8,969,952,992 $6,793,227,310 $5,457,072,340 $4,340,634,529
Cost Of Revenue $8,969,952,992 $6,793,227,310 $5,457,072,340 $4,340,634,529
Total Revenue $47,157,405,447 $44,310,084,688 $35,438,699,255 $26,999,881,977
Operating Revenue $111,296,353,355 $103,841,228,106 $92,867,881,857 $69,530,105,101
Expenses
Interest Expense $641,909,782 $250,233,430 $82,699,097 $57,675,754
Total Expenses $27,679,174,192 $24,727,945,527 $19,787,818,834 $15,585,423,017
Other Income Expense $924,795,623 $-161,278,498 $270,069,007 $-828,059,041
Net Non Operating Interest Income Expense $-485,056,143 $-13,884,904 $50,351,849 $-48,826,035
Total Other Finance Cost $36,772,108 $44,096,013 $30,058,528 $27,617,226
Interest Expense Non Operating $641,909,782 $250,233,430 $82,699,097 $57,675,754
Operating Expense $18,709,221,200 $17,934,718,217 $14,330,746,494 $11,244,788,488
Other Operating Expenses $45,774,408 $320,878,600 $-18,157,182 $-157,769,126
Selling And Marketing Expense $9,812,507,262 $9,475,455,037 $8,657,924,110 $7,051,852,715
General And Administrative Expense $910,758,138 $805,019,255 $740,782,503 $681,580,935
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Net Interest Income $-485,056,143 $-13,884,904 $50,351,849 $-48,826,035
Interest Income $193,625,746 $280,444,540 $163,109,474 $36,466,945
Normalized Income $14,901,801,728 $15,534,879,904 $12,562,555,725 $9,114,653,830
Net Income From Continuing And Discontinued Operation $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Total Operating Income As Reported $19,478,231,255 $19,582,139,161 $15,650,880,421 $11,414,458,960
Net Income Common Stockholders $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Net Income $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Net Income Including Noncontrolling Interests $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Net Income Continuous Operations $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Pretax Income $19,917,970,734 $19,406,975,760 $15,971,301,277 $10,537,573,884
Earnings From Equity Interest $-2,593,883 $-2,593,883 $12,359,090 $-28,837,877
Interest Income Non Operating $193,625,746 $280,444,540 $163,109,474 $36,466,945
Operating Income $19,478,231,255 $19,582,139,161 $15,650,880,421 $11,414,458,960
Gross Profit $38,187,452,455 $37,516,857,378 $29,981,626,915 $22,659,247,448
Per Share
Diluted EPS $3.51 $3.45 $2.84 $1.86
Basic EPS $3.52 $3.46 $2.85 $1.87
Other
Tax Effect Of Unusual Items $199,672,204 $-32,691,094 $51,799,693 $-156,647,348
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $22,986,534,465 $22,731,265,850 $17,232,538,798 $12,517,774,774
Total Unusual Items $927,389,506 $-158,684,614 $257,709,917 $-799,221,164
Total Unusual Items Excluding Goodwill $927,389,506 $-158,684,614 $257,709,917 $-799,221,164
Reconciled Depreciation $3,354,043,456 $2,915,372,046 $1,436,248,342 $1,123,303,972
EBITDA (Bullshit earnings) $23,913,923,971 $22,572,581,236 $17,490,248,715 $11,718,553,611
EBIT $20,559,880,516 $19,657,209,190 $16,054,000,374 $10,595,249,638
Diluted Average Shares $678,659,098 $680,970,610 $685,822,697 $693,421,249
Basic Average Shares $677,776,194 $679,582,119 $683,991,721 $691,285,110
Diluted NI Availto Com Stockholders $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Tax Provision $4,288,451,704 $3,998,089,376 $3,202,835,328 $2,065,493,870
Gain On Sale Of Security $927,389,506 $-158,684,614 $257,709,917 $-799,221,164
Research And Development $7,940,181,393 $7,333,365,324 $4,950,197,062 $3,669,123,964
Selling General And Administration $10,723,265,399 $10,280,474,293 $9,398,706,613 $7,733,433,650
Other Gand A $910,758,138 $805,019,255 $740,782,503 $681,580,935
Fetched: 2026-06-29
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $9,764,291,552 $4,984,070,124 $7,042,392,671 $4,966,065,524
Total Assets $82,836,725,507 $71,046,458,657 $47,984,701,581 $36,811,321,170
Total Non Current Assets $56,523,612,231 $46,360,625,585 $26,677,324,982 $20,302,933,506
Non Current Deferred Assets $3,608,091,420 $3,760,825,361 $3,109,608,117 $2,121,491,229
Non Current Deferred Taxes Assets $3,608,091,420 $3,760,825,361 $3,109,608,117 $2,121,491,229
Non Current Accounts Receivable $894,737,095 $612,766,742 $218,191,345 $31,431,760
Investmentin Financial Assets $326,676,692 $347,427,757 $191,184,444 $155,022,662
Goodwill And Other Intangible Assets $19,843,663,612 $16,909,218,897 $9,216,829,632 $7,772,341,897
Other Intangible Assets $16,815,686,523 $13,854,997,813 $8,535,706,441 $7,068,178,921
Current Assets $26,313,113,276 $24,685,833,072 $21,307,376,599 $16,508,387,664
Hedging Assets Current $1,019,548,648 $965,229,683 $357,650,708 $416,089,369
Inventory $7,571,544,827 $6,232,795,975 $4,853,765,643 $3,721,154,208
Receivables $13,608,121,173 $13,473,696,995 $11,483,425,735 $8,774,191,107
Other Receivables $2,057,101,896 $2,060,306,104 $1,231,026,412 $916,251,067
Taxes Receivable $739,714,433 $435,314,620 $369,704,635 $143,426,478
Accounts Receivable $10,811,304,844 $10,978,076,271 $9,882,694,687 $7,714,513,562
Allowance For Doubtful Accounts Receivable $-303,179,162 $-324,540,553 $-273,730,960 $-231,923,667
Gross Accounts Receivable $11,114,484,006 $11,302,616,823 $10,156,425,647 $7,946,437,229
Cash Cash Equivalents And Short Term Investments $4,113,898,628 $4,014,110,419 $4,612,534,513 $3,596,952,981
Cash And Cash Equivalents $4,037,913,111 $2,388,661,191 $2,195,950,933 $1,930,611,948
Cash Financial $4,037,913,111 $2,388,661,191 $2,195,950,933 $1,930,611,948
Debt
Net Debt $14,635,909,214 $12,262,353,578 $1,050,980,408 $1,312,504,859
Total Debt $19,981,749,743 $15,683,380,250 $4,120,612,208 $3,934,157,786
Long Term Debt And Capital Lease Obligation $18,148,179,540 $13,682,580,877 $3,132,190,158 $3,710,473,512
Long Term Debt $17,044,100,819 $12,854,369,255 $2,437,639,807 $3,169,877,754
Current Debt And Capital Lease Obligation $1,833,570,203 $2,000,799,374 $988,422,050 $223,684,274
Current Debt $1,629,721,506 $1,796,645,514 $809,291,533 $73,239,053
Other Current Borrowings $1,488,126,004 $912,894,277 $739,714,433 -
Liabilities
Total Liabilities Net Minority Interest $53,228,770,343 $49,153,169,636 $31,725,479,278 $24,072,913,749
Total Non Current Liabilities Net Minority Interest $20,322,921,664 $15,949,329,561 $5,839,288,647 $5,619,724,070
Tradeand Other Payables Non Current $160,363,009 $222,158,460 $28,837,877 $15,258,136
Non Current Deferred Liabilities $1,008,715,371 $841,486,200 $1,550,531,780 $1,077,376,983
Non Current Deferred Taxes Liabilities $1,008,715,371 $841,486,200 $1,550,531,780 $1,077,376,983
Current Liabilities $32,905,848,679 $33,203,840,075 $25,886,190,631 $18,453,189,678
Other Current Liabilities $6,369,814,036 $6,546,198,088 $4,573,931,429 $4,044,779,272
Payables And Accrued Expenses $24,645,399,011 $24,612,746,600 $4,992,767,262 $3,460,240,082
Payables $24,645,399,011 $24,612,746,600 $4,992,767,262 $3,460,240,082
Total Tax Payable $1,284,124,726 $1,482,480,494 $1,085,768,958 $1,081,954,424
Accounts Payable $23,361,274,286 $23,130,266,106 $3,906,998,304 $2,378,285,658
Other Non Current Liabilities - $3,509,371 $28,837,877 $15,258,136
Current Notes Payable - - - $0
Equity
Common Stock Equity $29,607,955,164 $21,893,289,021 $16,259,222,303 $12,738,407,421
Total Equity Gross Minority Interest $29,607,955,164 $21,893,289,021 $16,259,222,303 $12,738,407,421
Stockholders Equity $29,607,955,164 $21,893,289,021 $16,259,222,303 $12,738,407,421
Gains Losses Not Affecting Retained Earnings $-258,625,405 $-214,529,392 $194,693,815 $373,671,751
Other Equity Adjustments $-258,625,405 $-214,529,392 $194,693,815 $373,671,751
Retained Earnings $29,798,834,445 $22,040,072,289 $15,996,477,201 $12,296,074,058
Long Term Equity Investment $55,844,778 $61,032,544 $62,558,358 $49,894,105
Other
Treasury Shares Number $3,283,651 $3,610,004 $7,890,296 $9,185,398
Ordinary Shares Number $677,992,121 $677,665,769 $680,251,638 $686,585,604
Share Issued $681,275,772 $681,275,772 $688,141,934 $695,771,002
Tangible Book Value $9,764,291,552 $4,984,070,124 $7,042,392,671 $4,966,065,524
Invested Capital $48,281,777,489 $36,544,303,790 $19,506,153,644 $15,981,524,228
Working Capital $-6,592,735,403 $-8,518,007,003 $-4,578,814,032 $-1,944,802,015
Capital Lease Obligations $1,307,927,418 $1,032,365,482 $873,680,867 $691,040,979
Total Capitalization $46,652,055,983 $34,747,658,276 $18,696,862,110 $15,908,285,175
Treasury Stock $305,163 $305,163 $762,907 $915,488
Capital Stock $68,051,287 $68,051,287 $68,814,193 $69,577,100
Common Stock $68,051,287 $68,051,287 $68,814,193 $69,577,100
Employee Benefits $131,372,551 $137,780,968 $113,215,369 $116,266,996
Non Current Pension And Other Postretirement Benefit Plans $131,372,551 $137,780,968 $113,215,369 $116,266,996
Long Term Capital Lease Obligation $1,104,078,721 $828,211,622 $694,550,351 $540,595,758
Long Term Provisions $874,291,193 $1,065,323,056 $1,014,513,463 $700,348,442
Current Capital Lease Obligation $203,848,697 $204,153,860 $179,130,517 $150,445,221
Line Of Credit $27,922,389 $68,509,031 $69,577,100 $73,239,053
Commercial Paper $113,673,113 $815,242,206 $0 -
Current Provisions $57,065,429 $44,096,013 $15,331,069,890 $10,724,486,050
Investments And Advances $382,521,470 $408,460,301 $253,742,802 $204,916,766
Available For Sale Securities $326,676,692 $347,427,757 $191,184,444 $155,022,662
Investmentsin Associatesat Cost $55,844,778 $61,032,544 $62,558,358 $49,894,105
Goodwill $3,027,977,089 $3,054,221,083 $681,123,191 $704,162,976
Net PPE $31,794,598,634 $24,669,354,285 $13,878,953,087 $10,172,751,853
Accumulated Depreciation $-8,992,535,033 $-7,994,652,939 $-7,266,229,526 $-6,828,778,767
Gross PPE $40,787,133,667 $32,664,007,223 $21,145,182,613 $17,001,530,619
Construction In Progress $19,930,482,406 $13,045,248,536 $6,051,834,482 $3,411,871,791
Other Properties $1,695,636,654 $1,551,142,106 $1,370,028,031 $1,238,045,155
Machinery Furniture Equipment $9,157,933,227 $8,703,088,193 $6,248,359,273 $5,729,124,905
Properties $10,003,081,380 $9,364,528,389 $7,474,960,826 $6,622,488,768
Inventories Adjustments Allowances $-863,763,079 $-568,823,310 $-383,589,539 $-261,677,032
Finished Goods $1,829,450,506 $1,353,854,407 $1,102,247,745 $921,286,252
Work In Process $3,945,448,807 $3,407,904,676 $2,685,584,517 $2,086,244,935
Raw Materials $2,660,408,593 $2,039,860,202 $1,449,522,920 $975,300,053
Other Short Term Investments $75,985,517 $1,625,449,228 $2,416,583,580 $1,666,341,033
Fetched: 2026-06-29
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $4,423,181,045 $10,628,664,956 $10,682,526,176 $9,785,652,942
Operating Activities
Operating Cash Flow $18,172,745,139 $18,457,461,956 $16,617,330,755 $12,036,685,746
Cash Flow From Continuing Operating Activities $18,172,745,139 $18,457,461,956 $16,617,330,755 $12,036,685,746
Operating Gains Losses - $-1,682,514,657 $4,923,495,324 $21,056,228
Investing Activities
Capital Expenditure $-13,749,564,094 $-7,828,797,000 $-5,934,804,579 $-2,251,032,804
Investing Cash Flow $-12,078,035,295 $-19,666,974,397 $-6,697,101,053 $-3,802,022,328
Cash Flow From Continuing Investing Activities $-12,078,035,295 $-19,666,974,397 $-6,697,101,053 $-3,802,022,328
Financing Activities
Repurchase Of Capital Stock $-211,782,928 $-3,079,244,426 $-4,565,844,617 $-3,675,074,637
Financing Cash Flow $-4,334,531,275 $1,332,798,180 $-9,636,733,535 $-7,903,256,704
Cash Flow From Continuing Financing Activities $-4,334,531,275 $1,332,798,180 $-9,636,733,535 $-7,903,256,704
Cash Dividends Paid $-7,898,068,938 $-6,734,941,230 $-4,847,052,063 $-3,860,766,152
Net Common Stock Issuance $-211,782,928 $-3,079,244,426 $-4,565,844,617 $-3,675,074,637
Dividends Received Cfi - - $0 $0
Other
Repayment Of Debt $-12,082,612,736 $-966,602,916 $-223,836,855 $-2,078,615,867
Issuance Of Debt $15,857,933,326 $12,113,586,752 $0 $1,711,199,952
End Cash Position $4,037,913,111 $2,388,661,191 $2,195,950,933 $1,930,611,948
Beginning Cash Position $2,388,661,191 $2,195,950,933 $1,930,611,948 $1,635,519,598
Effect Of Exchange Rate Changes $-110,926,649 $69,424,519 $-18,157,182 $-36,314,364
Changes In Cash $1,760,178,569 $123,285,739 $283,496,167 $331,406,714
Common Stock Payments $-211,782,928 $-3,079,244,426 $-4,565,844,617 $-3,675,074,637
Net Issuance Payments Of Debt $3,775,320,590 $11,146,983,836 $-223,836,855 $-367,415,915
Net Long Term Debt Issuance $3,775,320,590 $11,146,983,836 $-223,836,855 $-367,415,915
Long Term Debt Payments $-12,082,612,736 $-966,602,916 $-223,836,855 $-2,078,615,867
Long Term Debt Issuance $15,857,933,326 $12,113,586,752 $0 $1,711,199,952
Net Investment Purchase And Sale $1,518,337,113 $698,364,885 $-762,296,475 $-471,476,402
Sale Of Investment $1,628,653,437 $3,721,611,952 $1,265,357,218 $1,013,903,137
Purchase Of Investment $-110,316,323 $-3,023,247,067 $-2,027,653,693 $-1,485,379,540
Net Business Purchase And Sale $153,191,685 $-12,536,542,282 $0 $-1,079,513,122
Sale Of Business $153,191,685 $0 $0 -
Purchase Of Business $0 $-12,536,542,282 $0 $-1,079,513,122
Net Intangibles Purchase And Sale $-4,573,321,103 $-632,449,737 $-1,997,290,002 $-397,779,606
Purchase Of Intangibles $-4,573,321,103 $-632,449,737 $-1,997,290,002 $-397,779,606
Net PPE Purchase And Sale $-9,176,242,990 $-7,196,347,263 $-3,937,514,576 $-1,853,253,199
Purchase Of PPE $-9,176,242,990 $-7,196,347,263 $-3,937,514,576 $-1,853,253,199
Taxes Refund Paid $-4,884,739,659 $-4,521,901,185 $-3,951,399,480 $-2,214,718,440
Interest Received Cfo $213,308,741 $287,463,282 $163,567,218 $42,112,455
Interest Paid Cfo $-521,675,670 $-93,379,792 $-74,917,448 $-41,502,130
Change In Working Capital $570,196,542 $395,033,141 $3,007,836,350 $-844,537,828
Other Non Cash Items $-476,359,006 $67,898,705 $64,694,497 $361,160,079
Deferred Tax $4,288,451,704 $3,998,089,376 $3,202,835,328 $2,065,493,870
Deferred Income Tax $4,288,451,704 $3,998,089,376 $3,202,835,328 $2,065,493,870
Depreciation Amortization Depletion $3,354,043,456 $2,915,372,046 $1,436,248,342 $1,123,303,972
Depreciation And Amortization $3,354,043,456 $2,915,372,046 $1,436,248,342 $1,123,303,972
Depreciation $3,354,043,456 $2,915,372,046 $1,436,248,342 $1,123,303,972
Net Income From Continuing Operations $15,629,519,030 $15,408,886,384 $12,768,465,949 $8,472,080,014
Change In Other Working Capital - $382,979,214 $-188,437,980 $176,994,378
Change In Other Current Liabilities - $1,391,847,166 $778,012,355 $571,569,775
Change In Payables And Accrued Expense - $-42,722,781 $1,157,634,778 $785,794,004
Change In Payable - $-42,722,781 $1,157,634,778 $785,794,004
Change In Account Payable - $494,363,606 $1,528,712,646 $1,024,888,995
Change In Inventory - $-1,379,030,332 $-1,132,611,435 $-727,355,343
Change In Receivables - $-2,183,286,680 $-2,482,956,471 $-1,651,540,641
Changes In Account Receivables - $-1,095,381,583 $-2,168,181,126 $-1,513,149,347
Stock Based Compensation - $349,258,733 $327,897,343 $234,822,713
Provisionand Write Offof Assets - $3,208,786,001 $4,917,697,233 $2,817,414,812
Asset Impairment Charge - $1,611,564,324 - $123,438,320
Amortization Cash Flow - $383,284,376 - $243,977,595
Amortization Of Intangibles - $383,284,376 - $243,977,595
Pension And Employee Benefit Expense - $-18,157,182 $4,919,680,790 $93,837,536
Earnings Losses From Equity Investments - $2,593,883 $-12,359,090 $28,837,877
Gain Loss On Investment Securities - $-774,960,727 $16,173,624 $392,439,258
Net Foreign Currency Exchange Gain Loss - $-891,990,631 $347,427,757 $-494,058,444
Sale Of PPE - - - $0
Fetched: 2026-06-29